UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

NCT03474497 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Metastatic Melanoma
Metastatic Renal Cell Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: IL-2
DRUG: Pembrolizumab
RADIATION: Radiotherapy

Sponsor

Megan Daly, MD

Collaborators

[object Object]